Novo Nordisk's REDEFINE 4 trial compared CagriSema and tirzepatide for weight loss over 84 weeks CagriSema achieved 23% weight loss with adherence versus 25.5% for tirzepatide 15 mg Weight loss was 20.2% with CagriSema and 23.6% with tirzepatide regardless of adherence
